Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFα degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2002
In the citing paper
“It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1α levels regardless of the availability of oxygen42.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [42]
In the citing paper
“GA can induce proteasomal degradation of HIF-1α in a VHL-independent manner both under normoxic and hypoxic conditions (Isaacs et al., 2002).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Isaacs et al., 2002
In the citing paper
“Heat shock protein 90 (HSP90) stabilizes HIF-1α under hypoxia and in tumors, and pharmacological inhibition of HSP90 promotes HIF-1α destabilization [183].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [183]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Research works printed but not linked: 18
- Wiesener, 2001, Cancer Res., 61, 5215
- Zhong, 1999, Cancer Res., 59, 5830
- Birner, 2000, Cancer Res., 60, 4693
- Akakura, 2001, Cancer Res., 61, 6548
- Griffiths, 2002, Cancer Res., 62, 688
- Takahashi, 1994, Cancer Res., 54, 4233
- Wizigmann-Voos, 1995, Cancer Res., 55, 1358
- Whitesell, 1992, Cancer Res., 52, 1721
- Shaknovich, 1992, Mol. Cell. Biol., 12, 5059
- Hostein, 2001, Cancer Res., 61, 4003
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- An, 2000, Cell Growth Differ., 11, 355
- Bonvini, 2002, Cancer Res., 62, 1559
- Adams, 1999, Cancer Res., 59, 2615
- Semenza, 1992, Mol. Cell. Biol., 12, 5447
- Hockel, 1999, Cancer Res., 59, 4525
- Mabjeesh, 2002, Cancer Res., 62, 2478
- Kruger, 2001, Clin. Cancer Res., 7, 1867
Cited by
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
“cgi?Q=hspca%20or%20hspcb%20not%20hspcal3&ORG=Hs">HSP90 , and the HSP90 inhibitor 17-allyl-aminogeldanamycin (17-AAG) induces HIF-1α degradation in a VHL-independent manne”
BackgroundOxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFa degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
BackgroundTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
“(2006) HSP90 inhibitors 17-AAG C Isaacs et al. (2002); Liu et al. (2007) Microtubule targeting agents Taxotere B Escuin et al. (2005) mTOR inhibitors Rapamycin B Zhong et al. (2000); Laughner et al.”
InfluentialHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Integration of Oxygen Signaling at the Consensus HRE
Wenger, R. H., Stiehl, D. P., & Camenisch, G. (2005) · Science's STKE · doi:10.1126/stke.3062005re12 · Cited by 1,032
Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
“cal Center, Dallas, TX) and FLAG-VHL (Isaacs et al., 2002).”
BackgroundMethodSelf-citationRegulation of Oxygen Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (2009) · Physiology · doi:10.1152/physiol.00045.2008 · Cited by 926
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894
Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1α
Lim, J.-H., Lee, Y.-M., Chun, Y.-S., Chen, J., Kim, J.-E., & Park, J.-W. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.023 · Cited by 758
“NT2 is known to affect the stability of HIF-1a via its interactions with Hsp90 and Rack1 (Isaacs et al., 2002; Liu et al., 2007).”
BackgroundThe von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
Kaelin Jr, W. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2502 · Cited by 726
Hypoxia and hypoxia-inducible factors: master regulators of metastasis
Lu, X., & Kang, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1360 · Cited by 723
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“Another mechanism of HDAC inhibitor action might be via Hsp90 inhibition, as described above.”
BackgroundInfluentialJung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J., & Neckers, L. (2003) · The FASEB Journal · doi:10.1096/fj.03-0329fje · Cited by 679
Self-citationPrabhakar, N. R., & Semenza, G. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00030.2011 · Cited by 641
“Binding of VHL is conditional, based on the hydroxylation of proline-564 (in human HIF-1 ) in well-oxygenated cells (134, 137, 371).”
BackgroundInfluentialHIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Self-citationHIF1 and oxygen sensing in the brain
Sharp, F. R., & Bernaudin, M. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1408 · Cited by 568
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Self-citationHypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 485
Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 479
“HIF-1a is a HSP90 client protein in renal cell carcinoma cells where its high expression is due to loss of the von Hippel Lindau gene product (48).”
BackgroundSmall molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Liu, Y. V., Baek, J. H., Zhang, H., Diez, R., Cole, R. N., & Semenza, G. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.001 · Cited by 478
“HSP90 binding stabilizes HIF-1α and disruption of HSP90-HIF-1α interaction by geldanamycin or 17-AAG results in HIF-1α degradation even in cells without functional VHL (Isaacs et al., 2002, 2004; Mabjeesh et al., 2002).”
BackgroundAngiogenesis Inhibitors: Current Strategies and Future Prospects
Cook, K. M., & Figg, W. D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 474
A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin
Willems, A. R., Schwab, M., & Tyers, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.027 · Cited by 464
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedTumor and its microenvironment: A synergistic interplay
Catalano, V., Turdo, A., Di Franco, S., Dieli, F., Todaro, M., & Stassi, G. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.007 · Cited by 444
Bruick, R. K. (2003) · Genes & Development · doi:10.1101/gad.1145503 · Cited by 440
“The PAS domains may also influence HIF activity through associations with hsp90 (Minet et al. 1999; Isaacs et al. 2002) and mediate target gene specificity via interactions with currently unidentified factors (Zelzer et al. 1997).”
BackgroundChaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu
Xu, W., Marcu, M., Yuan, X., Mimnaugh, E., Patterson, C., & Neckers, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202365899 · Cited by 433
Self-citationIntracellular localisation of human HIF-1α hydroxylases:implications for oxygen sensing
Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J. H., Stolze, I., Klinger, M., Huang, W. Q., Wotzlaw, C., Hellwig-Bürgel, T., Jelkmann, W., et al. (2003) · Journal of Cell Science · doi:10.1242/jcs.00318 · Cited by 432
“The existence of an oxygen- and pVHL-independent HIF-1α degradation pathway has been reported very recently (Isaacs et al., 2002).”
BackgroundLum, J. J., Bui, T., Gruber, M., Gordan, J. D., DeBerardinis, R. J., Covello, K. L., Simon, M. C., & Thompson, C. B. (2007) · Genes & Development · doi:10.1101/gad.1529107 · Cited by 429
“…stresses including reactive oxygen species (ROS), nitric oxide, and heat shock have also been reported to promote HIF-1 expression under normoxic conditions (Isaacs et al. 2002; Kasuno et al. 2004; Brunelle et al. 2005; Guzy et al. 2005; Lu et al. 2005; Mansfield et al. 2005; M. Wang et al. 2005).”
BackgroundNitric Oxide Impairs Normoxic Degradation of HIF-1α by Inhibition of Prolyl Hydroxylases
Metzen, E., Zhou, J., Jelkmann, W., Fandrey, J., & Brüne, B. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-12-0791 · Cited by 414
“However, recently, a pVHL- and oxygen-independent HIF-1 degradation pathway has been reported (Isaacs et al., 2002).”
BackgroundAn Acetylation Site in the Middle Domain of Hsp90 Regulates Chaperone Function
Scroggins, B. T., Robzyk, K., Wang, D., Marcu, M. G., Tsutsumi, S., Beebe, K., Cotter, R. J., Felts, S., Toft, D., Karnitz, L., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.008 · Cited by 413
“Plasmids, HSP90 Subcloning, Mutagenesis, and Transfection pcDNA3-ErbB2 was constructed as described (Tzahar et al., 1996). pcDNA3-HA-Hif1a and pcDNA3-CHIP were described previously (Isaacs et al., 2002; Xu et al., 2002).”
MethodSelf-citationNeckers, L., & Ivy, S. P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00003 · Cited by 400
Self-citationmTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R., & Tee, A. R. (2015) · Oncogene · doi:10.1038/onc.2014.164 · Cited by 391
Hyperglycemia Regulates Hypoxia-Inducible Factor-1α Protein Stability and Function
Catrina, S.-B., Okamoto, K., Pereira, T., Brismar, K., & Poellinger, L. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3226 · Cited by 384
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
Eltzschig, H. K., Bratton, D. L., & Colgan, S. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4422 · Cited by 366
Heat shock protein 90: The cancer chaperone
Neckers, L. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0051-y · Cited by 365
“HIF-1α interacts with Hsp90 (Gradin et al 1996), and both GA and another Hsp90 inhibitor, radicicol, reduce HIF-dependent transcriptional activity (Hur et al 2002, Isaacs et al 2002).”
BackgroundSelf-citationEvaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
Human high-altitude adaptation: forward genetics meets the HIF pathway
Bigham, A. W., & Lee, F. S. (2014) · Genes & Development · doi:10.1101/gad.250167.114 · Cited by 349
“HIF-a is known to be an HSP90 client (Minet et al. 1999; Isaacs et al. 2002; Katschinski et al. 2002); hence, the interaction of PHD2 with the PXLE motif contained within an HSP90 cochaperone (such as p23) or HSP90 itself could allow recruitment of PHD2 to the HSP90 pathway to facilitate HIF-a…”
BackgroundLonati, E., Brambilla, A., Milani, C., Masserini, M., Palestini, P., & Bulbarelli, A. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00001 · Cited by 347
“Since, unconventional VHL-independent HIF-1α degradation pathway involving RACK1 has been already described (Isaacs et al., 2002; Semenza, 2010), here we propose that Pin1/Gsk-3βmediated HIF-1α degradation may be a functionally predominant pathway in our cellular model, that instead of VHL requires…”
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Kaelin, W. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1865 · Cited by 336
Kaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
The hypoxia-inducible factor-1α is a negative factor for tumor therapy
Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E., Katschinski, D. M., & Wenger, R. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206385 · Cited by 334
“…small molecule inhibitors of HIF-1 (Rapisarda et al., 2002) and the finding that Hsp90 inhibitors of the ansamycin family strongly inhibit HIF-1 function (Isaacs et al., 2002; Katschinski et al., 2002; Mabjeesh et al., 2002) provide a first step towards a pharmacological anti-HIF-1 tumor therapy.”
BackgroundThe Hsp90 chaperone complex as a novel target for cancer therapy
Goetz, M. P., Toft, D. O., Ames, M. M., & Erlichman, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg316 · Cited by 334
“Treatment with GA prevents heat and hypoxia-induced HIF-1α expression [56], and in renal cell carcinoma cell lines, promotes HIF-1α ubiquitination and proteasomemediated degradation independent of the von Hippel–Lindau tumor suppressor gene [57].”
BackgroundHypoxia inducible factor-1α as a cancer drug target
Powis, G., & Kirkpatrick, L. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.647.3.5 · Cited by 311
VHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
Hypoxia-inducible Factor and Its Biomedical Relevance
Huang, L. E., & Bunn, H. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r200030200 · Cited by 315
Semenza, G. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.69 · Cited by 297
Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309
“Other regulators of HIF-1a include human double minute 2 (also known as MDM2), which is recruited to HIF-1a by p53 resulting in human double minute 2–mediated HIF-1a ubiquitination and proteasomal degradation (12), and heat shock protein 90, which binds to HIF-1a to prevent its degradation (13).”
BackgroundThe tumor microenvironment and metastatic disease
Lunt, S. J., Chaudary, N., & Hill, R. P. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9182-2 · Cited by 298
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P., & Pili, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 299
“Previously, the Hsp90 inhibitor–initiated HIF-1a degradation in C2 cells was reported as VHL independent ( 18 ).”
BackgroundPharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
Negative and positive regulation of HIF-1: A complex network
Bárdos, J. I., & Ashcroft, M. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.05.001 · Cited by 285
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
Xia, Y., Choi, H.-K., & Lee, K. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.033 · Cited by 278
Development of HIF‐1 inhibitors for cancer therapy
Onnis, B., Rapisarda, A., & Melillo, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00876.x · Cited by 268
Role of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α
Chan, D. A., Sutphin, P. D., Denko, N. C., & Giaccia, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206922200 · Cited by 264
Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2019-2028.2006 · Cited by 258
“The role of the ubiquitin system in the non-oxygenrelated degradation of HIF-1 was further explored by the use of 17AAG, a HSP90 inhibitor known to suppress HIF-1 expression ( 20 , 27).”
BackgroundMethodInfluentialHypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair
Shu, S., Wang, Y., Zheng, M., Liu, Z., Cai, J., Tang, C., & Dong, Z. (2019) · Cells · doi:10.3390/cells8030207 · Cited by 259
“In addition, heat shock protein 90 (HSP90) inhibitors and histone deacetylase inhibitors (HDACIs) were reported to accelerate HIF-α degradation in a manner independent of pVHL [57,58].”
BackgroundReview: Hypoxia-Inducible Factor-1 (HIF-1): A Novel Transcription Factor in Immune Reactions
Hellwig-Bürgel, T., Stiehl, D. P., Wagner, A. E., Metzen, E., & Jelkmann, W. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.297 · Cited by 254
Hypoxia-Inducible Factor-1α and the Glycolytic Phenotype in Tumors
Robey, I. F., Lien, A. D., Welsh, S. J., Baggett, B. K., & Gillies, R. J. (2005) · Neoplasia · doi:10.1593/neo.04430 · Cited by 251
Development and application of Hsp90 inhibitors
Solit, D. B., & Chiosis, G. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.007 · Cited by 251
A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy
Turcotte, S., Chan, D. A., Sutphin, P. D., Hay, M. P., Denny, W. A., & Giaccia, A. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.004 · Cited by 251
“Cell-based small-molecule screening has been used to identify compounds that inhibit specific proteins, such as HIF, or to overcome drug resistance to reduce tumorigenicity (Isaacs et al., 2002; Mabjeesh et al., 2003; Rapisarda et al., 2002; Smukste et al., 2006).”
The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses
Bracken, C. P., Whitelaw, M. L., & Peet, D. J. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-2370-y · Cited by 251
(2003) · PubMed · Cited by 250
Genetic Basis of Cancer of the Kidney
Linehan, W. M., Vasselli, J., Srinivasan, R., Walther, M. M., Merino, M., Choyke, P., Vocke, C., Schmidt, L., Isaacs, J. S., Glenn, G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050013 · Cited by 251
Self-citationQiu, G.-Z., Jin, M.-Z., Dai, J.-X., Sun, W., Feng, J.-H., & Jin, W.-L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.002 · Cited by 245
The Warburg effect: Insights from the past decade
Upadhyay, M., Samal, J., Kandpal, M., Singh, O. V., & Vivekanandan, P. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.11.003 · Cited by 243
Heat Shock Protein 90 as a Drug Target: Some Like It Hot
Banerji, U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0132 · Cited by 244
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., Regan, M., & Kaelin, W. G. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601300 · Cited by 235
“The levels of HA-HIF1a were lower than that of HA-HIF2a, possibly due to the existence of pVHL-independent ubiquitin ligases that can target HIF1a (Ravi et al, 2000; Isaacs et al, 2002).”
BackgroundNon-Canonical Mechanisms Regulating Hypoxia-Inducible Factor 1 Alpha in Cancer
Iommarini, L., Porcelli, A. M., Gasparre, G., & Kurelac, I. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00286 · Cited by 231
Cellular oxygen sensing need in CNS function: physiological and pathological implications
Acker, T., & Acker, H. (2004) · Journal of Experimental Biology · doi:10.1242/jeb.01075 · Cited by 231
“…recently suggested by studies reporting that heat shock proteins Hsp70 and Hsp90 protect HIF-1α from proteosomal degradation by physical interaction and support HIF-α transcriptional activity (Gradin et al., 1996; Minet et al., 1999; Mabjeesh et al., 2002; Isaacs et al., 2002; Zhou et al., 2004).”
BackgroundTargeting hypoxia cell signaling for cancer therapy
Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230
Ellinghaus, P., Heisler, I., Unterschemmann, K., Haerter, M., Beck, H., Greschat, S., Ehrmann, A., Summer, H., Flamme, I., Oehme, F., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.112 · Cited by 229
“Most of these compounds affect HIF-1 target gene expression only at micromolar concentrations like PX-478 [29] and acriflavine [21] or display distinct pharmacological profiles with primary modes of action different from direct HIF-1 inhibition that may rather explain their antitumor efficacy in preclinical cancer mod…”
BackgroundZhou, J., Schmid, T., Frank, R., & Brüne, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310164200 · Cited by 225
Identification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway
Tan, C., de Noronha, R. G., Roecker, A. J., Pyrzynska, B., Khwaja, F., Zhang, Z., Zhang, H., Teng, Q., Nicholson, A. C., Giannakakou, P., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.605.65.2 · Cited by 225
“These include the microtubule destabilizer 2-methoxyestradiol (25), the HSP90 inhibitor 17-allyl-amino-geldanamycin (26), thioredoxin inhibitors 1-methylpropyl-2-imidazolyl disulfide (27), the topoisomerase inhibitors camptothecin and topotecan (28), and the mammalian target of rapamycin (mTOR) kinase inhibitor CCI-77…”
BackgroundNovel approaches in the therapy of metastatic renal cell carcinoma
Lam, J. S., Leppert, J. T., Belldegrun, A. S., & Figlin, R. A. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0466-0 · Cited by 223
Drogat, B., Auguste, P., Nguyen, D. T., Bouchecareilh, M., Pineau, R., Nalbantoglu, J., Kaufman, R. J., Chevet, E., Bikfalvi, A., & Moenner, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3235 · Cited by 220
“In keeping with this result, the expression of Hsp90, whose function has been linked to the maintenance of HIF-1 mRNA and protein ( 45 , 46), also decreases in IRE1 DN–expressing cells (data not shown).”
BackgroundCHIP: a quality-control E3 ligase collaborating with molecular chaperones
Murata, S., Chiba, T., & Tanaka, K. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00394-1 · Cited by 218
Xu, W., & Neckers, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2966 · Cited by 218
Self-citationKelly, T. J., Souza, A. L., Clish, C. B., & Puigserver, P. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01242-10 · Cited by 218
Understanding Command and Control
Alberts, D. S., & Hayes, R. E. (2006) · Defense Technical Information Center (DTIC) · Cited by 281
Adaptation to Oxidative Stress, Chemoresistance, and Cell Survival
Landriscina, M., Maddalena, F., Laudiero, G., & Esposito, F. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2692 · Cited by 217
Apigenin inhibits tumor angiogenesis through decreasing HIF-1 and VEGF expression
Fang, J., Zhou, Q., Liu, L.-Z., Xia, C., Hu, X., Shi, X., & Jiang, B.-H. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl205 · Cited by 216
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
Kaelin, W. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.165 · Cited by 214
Regulation of HIF prolyl hydroxylases by hypoxia‐inducible factors
Aprelikova, O., Chandramouli, G. V. R., Wood, M., Vasselli, J. R., Riss, J., Maranchie, J. K., Linehan, W. M., & Barrett, J. C. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20067 · Cited by 214
“Besides conditions of low oxygen, the p53 tumor suppressor gene and Hsp90 control HIF1a degradation [Ravi et al., 2000; Isaacs et al., 2002].”
BackgroundTargeting the hypoxia-inducible factor (HIF) pathway in cancer
Poon, E., Harris, A. L., & Ashcroft, M. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001173 · Cited by 213
Ubiquitin-independent degradation of proteins by the proteasome
Jariel-Encontre, I., Bossis, G., & Piechaczyk, M. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.004 · Cited by 201
Semenza, G. L. (2013) · Oncogene · doi:10.1038/onc.2012.578 · Cited by 201
JUNG, Y., ISAACS, J. S., LEE, S., TREPEL, J., LIU, Z.-G., & NECKERS, L. (2003) · Biochemical Journal · doi:10.1042/bj20021279 · Cited by 198
Self-citationUbiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT
Kim, J. H., Park, S.-M., Kang, M. R., Oh, S.-Y., Lee, T. H., Muller, M. T., & Chung, I. K. (2005) · Genes & Development · doi:10.1101/gad.1289405 · Cited by 197
“GA-mediated protein degradation by the proteasome depends on conjugation of ubiquitin to the Hsp90 client protein (Isaacs et al. 2002).”
BackgroundResultHDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia
Geng, H., Harvey, C. T., Pittsenbarger, J., Liu, Q., Beer, T. M., Xue, C., & Qian, D. Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257055 · Cited by 197
Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
Yu, T., Tang, B., & Sun, X. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.489 · Cited by 191
Hypoxia in tissue repair and fibrosis
Darby, I. A., & Hewitson, T. D. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2461-3 · Cited by 188
Metadata
- Authors
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 277
- Issue
- 33
- Pages
- 29936-29944
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022471909
- Cited by
- 663
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 32 · 2020: 19 · 2019: 20 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 30 · 2014: 31 · 2013: 27 · 2012: 41
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6667 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HSP90, HIF-1α, VHL, hypoxia, protein degradation, geldanamycin, E3 ubiquitin ligase, proteasome, renal carcinoma, angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, hypoxic cell radiosensitizers
- MeSH terms
- Cysteine Endopeptidases, Hydrolysis, Ligases, Multienzyme Complexes, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Down-Regulation, HSP90 Heat-Shock Proteins, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.